• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by BGM Group Ltd.

    12/3/24 6:03:06 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGM alert in real time by email
    SC 13D 1 tm2429887d1_sc13d.htm SC 13D

     

     

     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

    Schedule 13D

    Under the Securities Exchange Act of 1934

     

    BGM Group Ltd
    (Name of Issuer)

     

    Class A Ordinary Shares, par value $0.00833335 per share

    (Title of Class of Securities)

     

    G7307E123**

    (CUSIP Number)

     

    Furong Cao

    Flat 1512, 15/F, Lucky Centre

    No.165-171 Wan Chai Road

    Wan Chai, 999077, Hong Kong

    +86-157-56256951

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    November 1, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    **This refers only to the CUSIP of the Class A ordinary shares, par value $0.00833335 each, of the Issuer. There is no CUSIP for the Class B ordinary shares, par value $0.00833335 each, of the Issuer.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G7307E123 Page 2 of 6 Pages

     

    (1)

    Names of reporting person:

     

    LX Management Company Limited

    (2)

    Check the appropriate box if a member of a group (see instructions)

    (a) ¨

    (b) ¨

    (3)

    SEC use only

     

     
    (4)

    Source of funds (see instructions)

     

    OO

    (5)

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

    ¨

    (6)

    Citizenship or place of organization

     

    Hong Kong

    Number of

    shares beneficially owned

    by each reporting person

    with:

    (7)

    Sole voting power

     

    0

    (8)

    Shared voting power

     

    9,800,000 Class B ordinary shares

    (9)

    Sole dispositive power

     

    0

    (10)

    Shared dispositive power

     

    9,800,000 Class B ordinary shares

    (11)

    Aggregate amount beneficially owned by each reporting person

     

    9,800,000 Class B ordinary shares

    (12)

    Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    ¨

    (13)

    Percent of class represented by amount in Row (11)

     

    49.0% of the issued and outstanding Class B ordinary shares(**)

    (14)

    Type of reporting person (see instructions)

     

    CO

           

     

     

     

    CUSIP No. G7307E123 Page 3 of 6 Pages

     

    (1)

    Names of reporting person:

     

    Furong Cao

    (2)

    Check the appropriate box if a member of a group (see instructions)

    (a) ¨

    (b) ¨

    (3)

    SEC use only

     

     
    (4)

    Source of funds (see instructions)

     

    OO

    (5)

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

    ¨

    (6)

    Citizenship or place of organization

     

    People’s Republic of China

    Number of

    shares beneficially owned

    by each reporting person

    with:

    (7)

    Sole voting power

     

    9,800,000 Class B ordinary shares (*)

    (8)

    Shared voting power

     

    0

    (9)

    Sole dispositive power

     

    9,800,000 Class B ordinary shares (*)

    (10)

    Shared dispositive power

     

    0

    (11)

    Aggregate amount beneficially owned by each reporting person

     

    9,800,000 Class B ordinary shares (*)

    (12)

    Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    ¨

    (13)

    Percent of class represented by amount in Row (11)

     

    49.0% of the issued and outstanding Class B ordinary shares (**)

    (14)

    Type of reporting person (see instructions)

     

    IN

           

    * Representing 9,800,000 Class B ordinary shares of the Issuer (the “Class B Ordinary Shares”) held indirectly by Ms. Furong Cao, through LX Management Company Limited. LX Management Company Limited is wholly owned by Ms. Furong Cao. According to the third amended and restated memorandum and articles of association (the “Third M&A”) of the Issuer, each Class B Ordinary Share is convertible, at the option of the holder thereof, with the consent of the directors by a vast majority of no less than two-thirds votes at a board meeting or by the written resolutions of all the directors, into one Class A ordinary share of the Issuer (each a “Class A Ordinary Share”). Each Class B Ordinary Share is entitled to one hundred (100) votes on all matters subject to vote at general meetings of the Issuer, whereas each Class A Ordinary Share is entitled to one (1) vote.

     

    ** Based on 20,000,000 issued and outstanding Class B Ordinary Shares

     

     

     

     

    CUSIP No. G7307E123 Page 4 of 6 Pages

     

    Item 1. Security and Issuer.

     

    This Schedule 13D relates to the Class A Ordinary Shares, par value of $0.00833335, of BGM Group Ltd (the “Issuer” or “Company”), whose principal executive offices are located at No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District, Chengdu, 610200, People’s Republic of China.

     

    Item 2. Identity and Background.

     

    (a) Name & Citizenship:

     

    (i) Furong Cao (“Ms. Cao”), a citizen of the People’s Republic of China; and

     

    (ii) LX Management Company Limited (“LX Management”), a company established in Hong Kong;

     

    (collectively, the “Reporting Persons”)

     

    (b) Residence or business address:

     

    (i) The residential address of Ms. Cao is 14B West Tower, Huarun Vientiane Mansion, Yuehai Street, Nanshan District, Shenzhen, 518000, People’s Republic of China.

     

    (ii) The business address of LX Management is Flat 1512, 15/F, Lucky Centre, No.165-171 Wan Chai Road, Wan Chai, 999077, Hong Kong.

     

    (c) Principal business of each reporting person and address:

     

    Ms. Cao is the sole director of LX Management and a director of the Issuer.

     

    LX Management is a holding company with no actual operations.

     

    (d) — (e) During the last five years, the Reporting Persons have not been: (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    On November 1, 2024, the Issuer entered into a share subscription agreement (the “Share Subscription Agreement”) with LX Management. Pursuant to the Share Subscription Agreement, the Issuer agreed to issue to LX Management 9,800,000 Class B ordinary shares of par value of US$0.00833335 each of the Issuer (the “Subscription Shares”, each “a Subscription Share”). The purchase price per Subscription Share is US$0.05 and LX Management agreed to pay to the Issuer a total consideration of US$490,000. The Subscription Shares are expected to be issued on or around November 27, 2024. Following the issuance of the Subscription Shares, Ms. Cao beneficially owns 9,800,000 Class B ordinary shares, representing 48.8% of the total voting power. LX Management holds 9,800,000 Class B ordinary shares, representing 48.8% of the total voting power.

     

    The Share Subscription Agreement has been filed by the Issuer with the SEC as Exhibit 99.1 on Form 6-K on November 27, 2024, which is hereby incorporated by reference.

     

     

     

     

    CUSIP No. G7307E123 Page 5 of 6 Pages

     

    Item 4. Purpose of Transaction.

     

    The information set forth in Item 3 is hereby incorporated by reference. The Reporting Persons acquired the Subscription Shares for investment purposes. Except as set forth above, the Reporting Persons do not have any present plan or proposal as a stockholder which relates to, or would result in any action with respect to, the matters listed in paragraphs (a) through (j) of Item 4 of Schedule 13D.

     

    Item 5. Interest in Securities of the Issuer.

     

    (a) — (c) The responses of each Reporting Person to Rows (7) through (13), including the footnotes thereto, of the cover pages of this Schedule 13D are hereby incorporated by reference in this Item 5. The information set forth in Item 2, 3 and 4 above is hereby incorporated by reference. Except as disclosed in this Schedule 13D, none of the Reporting Persons has effected any transaction in the ordinary shares of the Issuer during the past 60 days.

     

    (d) – (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

     

    The information set forth in Item 3, Item 4 and Item 5 of this Schedule 13D is incorporated by reference.

     

    Item 7. Material to be Filed as Exhibits.

     

    A joint filing agreement by both of the Reporting Persons is attached as Exhibit 99.1.

     

    LIST OF EXHIBITS

     

    Exhibit No.   Description
    99.1   Joint Filing Agreement

     

     

     

     

    CUSIP No. G7307E123 Page 6 of 6 Pages

     

    Signatures

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 3, 2024

     

      /s/ Furong Cao
      Name: Furong Cao 
       
      LX Management Company Limited
       
      /s/ Furong Cao
      Name: Furong Cao
      Title: Sole Director

     

     

    Get the next $BGM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by BGM Group Ltd.

      SC 13D - BGM Group Ltd. (0001779578) (Subject)

      12/3/24 6:03:06 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BGM Group Ltd.

      SC 13D/A - BGM Group Ltd. (0001779578) (Subject)

      11/29/24 9:00:27 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Qilian International Holding Group Ltd.

      SC 13D - Qilian International Holding Group Ltd (0001779578) (Subject)

      10/16/24 4:19:46 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    SEC Filings

    See more
    • SEC Form 6-K filed by BGM Group Ltd.

      6-K - BGM Group Ltd. (0001779578) (Filer)

      5/28/25 4:30:18 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by BGM Group Ltd.

      SCHEDULE 13G - BGM Group Ltd. (0001779578) (Subject)

      5/28/25 6:35:46 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by BGM Group Ltd.

      SCHEDULE 13D/A - BGM Group Ltd. (0001779578) (Subject)

      5/27/25 4:30:03 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts

      CHENGDU, China, May 28, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM)  (NASDAQ:BGM) today announced that it has entered into definitive transaction agreements with the existing shareholders of Xingdao Intelligent Cloud Chain (Shenzhen) Co., Ltd. ("Xingdao Intelligent") and YD Network Technology Company Limited ("YD Network"). Under the terms of the agreements, BGM will acquire 100% of the equity interests of both companies at a combined valuation of RMB800 million. The consideration will be paid through the issuance of 37,123,142 newly issued Class A ordinary shares of BGM at a price of US$3.0 per share. The transactions are expected to close by the end of June 2025, subject to

      5/28/25 4:30:00 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Group Announces Strategic Acquisition of HM Management to Expand AI Application Ecosystem

      CHENGDU, China, May 2, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) (the "Company" or "BGM") , a leading AI technology company, today announced it has entered into a definitive agreement (the "Agreement") to acquire HM Management Company Limited ("HM Management"), a prominent AI agent production platform, in an all-stock transaction valued at approximately RMB300 million (US$41.7 million). Under the Agreement, BGM will issue 16,663,427 Class A ordinary shares at $2.50 per share to acquire 100% ownership of HM Management and its two wholly-owned subsidiaries: Beijing Shuda Technology Company Limited. ("Shuda Technology") and New Media Star Technology (Shenzhen) Co., Ltd ( "New Media Star

      5/2/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Completes Acquisition of YX to Advance AI-Powered Intelligent Platform

      CHENGDU, China, April 28, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) (the "Company" or BGM)  today announced the completion of its acquisition of YX Management Company Ltd. ("YX"), an leading intelligent mobility technology platform, on April 25, 2025. As previously disclosed, BGM acquired 100% of YX by issuing 47.5 million Class A ordinary shares to YX's existing shareholders, representing a valuation of US$95.0 million. Upon completion of the acquisition, YX's shareholders collectively own approximately 32.6% of BGM's equity interests and approximately 2.2% of the total voting power. This acquisition represents a significant step in BGM's AI-driven transformation, enhancing its capa

      4/28/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    Leadership Updates

    Live Leadership Updates

    See more
    • BGM Group Announces Board Reshuffle: New Leadership Embarks on a Transformative Journey Amid Tech Revolution

      CHENGDU, China, Feb. 28, 2025 /PRNewswire/ -- BGM Group Ltd (NASDAQ:BGM) (the "Company" or "BGM") today announced changes to its board of directors, marking the Company's entry into a new phase of technological transformation and sustainable growth. Mr. Zhanchang Xin has tendered his resignation and will step down from his role as Chairman of the Company, effective March 1, 2025. He will be succeeded by Mr. Chen Xin, the current Chief Executive Officer of the Company, who will assume the position of Chairman. As the founder of the Company, Mr. Zhanchang Xin has, over the past six decades, has played a pivotal role in leading the Company through numerous challenges and milestones, including

      2/28/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Group Establishes "Duxiaobao Management Committee" to Accelerate AI Strategy and Drive Intelligent Transformation in the Insurance Industry

      CHENGDU, China, Feb. 19, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) announced the establishment of the "Duxiaobao Management Committee," which will be fully responsible for the management and decision-making of the "Duxiaobao" ecosystem. This move signifies BGM Group's strategic entry into the field of artificial intelligence, aiming to accelerate the transformation of the insurance industry into the smart era through AI technology. The Duxiaobao Management Committee consists of industry leaders such as Xin Chen, Li Yuqing, Ge Peng, Zhao Qi, Ren Yong, Li Jun, Zhou Xin, and Wang Hui. The committee has appointed Li Yuqing as the CEO of Duxiaobao, with Li Jun, Ren Yong, Zhou Xin, and Tan

      2/19/25 7:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    Financials

    Live finance-specific insights

    See more
    • From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts

      CHENGDU, China, May 28, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM)  (NASDAQ:BGM) today announced that it has entered into definitive transaction agreements with the existing shareholders of Xingdao Intelligent Cloud Chain (Shenzhen) Co., Ltd. ("Xingdao Intelligent") and YD Network Technology Company Limited ("YD Network"). Under the terms of the agreements, BGM will acquire 100% of the equity interests of both companies at a combined valuation of RMB800 million. The consideration will be paid through the issuance of 37,123,142 newly issued Class A ordinary shares of BGM at a price of US$3.0 per share. The transactions are expected to close by the end of June 2025, subject to

      5/28/25 4:30:00 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy

      CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of the equity interests of Wonder Dragon by issuing 38,165,290 Class A ordinary shares at a price of $2 per share, for a total transaction valuation of RMB550 million. The transaction is expected to be completed in the second quarter of 2025. Wonder Dragon possesses over 3,000 metric tons of premium Qingzhuan dark tea inventory, comprising 1,670 metric tons of raw materials and 1,350 metric tons of finished products. These premium tea products, known f

      4/21/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Acquires YX to Strengthen AI Strategy for Its Intelligent Platform

      CHENGDU, China, March 19, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM) (NASDAQ:BGM) today announced that it has signed a definitive agreement with the existing shareholders of YX Management Company Ltd. ("YX"), a smart mobility technology company. Under the agreement, BGM will acquire 100% of the equity interests of YX by issuing 47.5 million class A ordinary shares to its existing shareholders, valuing YX at US$95.0 million. This acquisition is based on the exceptional expertise and experience of the YX team in scalable operations, digital infrastructure development, and technology commercialization. The integration of this team will accelerate the AI-driven strategic upgrade

      3/19/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care